Unifying mechanism and methods to prevent cancer and neurodegenerative diseases

• US 20050164911A1
• Filed: 09/14/2004
• Published: 07/28/2005
• Est. Priority Date: 03/14/2002
• Status: Abandoned Application

• Current Assignee: Prevention, LLC
• Original Assignee: Prevention, LLC
• Inventors: Rogan, Eleanor, Cavalieri, Ercole L.
• Application Number:
  US10/940,600
• Publication Number:
  US 20050164911A1
• Time in Patent Office: Days
• US Class Current: 514/613
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/381 having five-membered rings
• CPC Class Codes: A61K 31/385 having two or more sulfur atoms in the same ring
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/4045 Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

The present invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering N-Acetylcysteine (NAC), melatonin, or a combination thereof. The present invention also relates to methods for diagnosing cancer and/or neurdegenerative disease by detecting or determining the amount of dopamine metabolites, 4-CE, 2-CE, methylation of CE or CE-Q conjugates.

Claims

1. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (canceled)

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. (canceled)

31. (canceled)

32. (canceled)

33. A pharmaceutical composition comprising 1) NAC or a physiologically acceptable salt thereof, 2) melatonin or a physiologically acceptable salt thereof, 3) optionally one or more agents that induce quinone reductase, and 4) one or more physiologically acceptable carriers or excipients.

2. A method for preventing or reducing the risk of neurodegenerative disease in a mammal comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition of claim 33.

3. A method for preventing or reducing the risk of cancer in a mammal comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition of claim 33.

4. A method for preventing or reducing the risk of neurodegenerative disease and cancer in a mammal comprising administering to the mammal the pharmaceutical composition of claim 33.

34. The composition of claim 33 that comprises lipoic acid or a pharmaceutically acceptable salt thereof.

35. The composition of claim 33 that comprises resveratrol or a pharmaceutically acceptable salt thereof.

36. The composition of claim 34 that comprises resveratrol or a pharmaceutically acceptable salt thereof.

37. A method for preventing or reducing the risk of neurodegenerative disease in a mammal comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition of claim 34.

38. A method for preventing or reducing the risk of neurodegenerative disease in a mammal comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition of claim 35.

39. A method for preventing or reducing the risk of neurodegenerative disease in a mammal comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition of claim 36.

40. A method for preventing or reducing the risk of cancer in a mammal comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition of claim 34.

41. A method for preventing or reducing the risk of cancer in a mammal comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition of claim 35.

42. A method for preventing or reducing the risk of cancer in a mammal comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition of claim 36.

43. A method for preventing or reducing the risk of neurodegenerative disease and cancer in a mammal comprising administering to the mammal the pharmaceutical composition of claim 34.

44. A method for preventing or reducing the risk of neurodegenerative disease and cancer in a mammal comprising administering to the mammal the pharmaceutical composition of claim 35.

45. A method for preventing or reducing the risk of neurodegenerative disease and cancer in a mammal comprising administering to the mammal the pharmaceutical composition of claim 36.

46. A method for preventing or reducing the risk of neurodegenerative disease by administering 1) NAC or a physiologically acceptable salt thereof, 2) melatonin, 3) lipoic acid, 4) resveratrol together or in any combination thereof.

47. A method for preventing or reducing the risk of cancer by administering 1) NAC or a physiologically acceptable salt thereof, 2) melatonin, 3) lipoic acid, 4) resveratrol together or in any combination thereof.

48. A method for preventing or reducing the risk of neurodegenerative disease and cancer by administering 1) NAC or a physiologically acceptable salt thereof, 2) melatonin, 3) lipoic acid, 4) resveratrol together or in any combination thereof.